<DOC>
	<DOCNO>NCT01356680</DOCNO>
	<brief_summary>This study design test non-inferiority experimental arm compare standard arm term progression free survival ( PFS ) .</brief_summary>
	<brief_title>HD17 Intermediate Stage Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin Lymphoma CS I , II risk factor ( stage IIB risk factor 1 2 include ) large mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) extranodal involvement elevate ESR 3 involve nodal area write informed consent Leucocytes &lt; 3000/µl Platelets &lt; 100000/µl Hodgkin Lymphoma composite lymphoma Activity Index ( WHO ) &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>intermediate stage</keyword>
	<keyword>PET</keyword>
</DOC>